Irby Danielle, Du Chengan, Li Feng
Department of Pharmaceutical Sciences, School of Pharmacy, Hampton University , Hampton, Virginia 23668, United States.
Mol Pharm. 2017 May 1;14(5):1325-1338. doi: 10.1021/acs.molpharmaceut.6b01027. Epub 2017 Jan 24.
Lipid-drug conjugates (LDCs) are drug molecules that have been covalently modified with lipids. The conjugation of lipids to drug molecules increases lipophilicity and also changes other properties of drugs. The conjugates demonstrate several advantages including improved oral bioavailability, improved targeting to the lymphatic system, enhanced tumor targeting, and reduced toxicity. Based on the chemical nature of drugs and lipids, various conjugation strategies and chemical linkers can be utilized to synthesize LDCs. Linkers and/or conjugation methods determine how drugs are released from LDCs and are critical for the optimal performance of LDCs. In this review, different lipids used for preparing LDCs and various conjugation strategies are summarized. Although LDCs can be administered without a delivery carrier, most of them are loaded into appropriate delivery systems. The lipid moiety in the conjugates can significantly enhance drug loading into hydrophobic components of delivery carriers and thus generate formulations with high drug loading and superior stability. Different delivery carriers such as emulsions, liposomes, micelles, lipid nanoparticles, and polymer nanoparticles are also discussed in this review.
脂质-药物偶联物(LDCs)是已与脂质共价修饰的药物分子。脂质与药物分子的偶联增加了亲脂性,同时也改变了药物的其他性质。这些偶联物具有多种优势,包括提高口服生物利用度、改善对淋巴系统的靶向性、增强肿瘤靶向性以及降低毒性。基于药物和脂质的化学性质,可以采用各种偶联策略和化学连接子来合成LDCs。连接子和/或偶联方法决定了药物如何从LDCs中释放出来,对LDCs的最佳性能至关重要。在本综述中,总结了用于制备LDCs的不同脂质和各种偶联策略。尽管LDCs可以在没有递送载体的情况下给药,但大多数LDCs被装载到合适的递送系统中。偶联物中的脂质部分可以显著提高药物向递送载体疏水成分中的装载量,从而产生具有高药物装载量和优异稳定性的制剂。本综述还讨论了不同的递送载体,如乳液、脂质体、胶束、脂质纳米颗粒和聚合物纳米颗粒。